Markets
local & international
Asia Pacific
Currencies
Commodities
UK
North America
News
latest news
Latest News
Most Viewed
Business
Currencies
Economy
Markets
Property
Technology
Portfolio
analysis & tools
Portfolios
Alerts
Filters
Reports
Watchlists
Help
Products
products & services
Charting
Data Agent
Data Subscriptions
Historical Data
Investment Game
Pricing
Real Edge
Download
Login
Register
Friday, 29 March 2024
Faron Pharmaceuticals Oy
LSE
FARN
Summary
|
Chart
|
News
|
History
|
More info..
LSE : FARN
162.50
14 Oct 22 00:00
Change:
12.50
Open:
170.00
High:
170.00
Ask:
0.00
Volume:
23,970
Change(%):
7.14
Prev:
175.00
Low:
155.30
Bid:
0.00
Avg vol:
0
Latest News
More news...
Faron Pharmaceuticals Oy (FARN) Moved Up 0.62% on Feb 27
22:11 | 27/2/18
BZ Weekly
Shares of Faron Pharmaceuticals Oy (LON:FARN) last traded at 888, representing a move of 0.62%, or 5.5 per share, on volume of 1,100 shares.
more»
A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine ...
01:23 | 22/2/18
Proactive Investors UK
Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products.
more»
Faron Pharmaceuticals Oy (FARN) Soars 2.38% on Feb 19
05:30 | 20/2/18
WeeklyHub
Shares of Faron Pharmaceuticals Oy (LON:FARN) last traded at 860, representing a move of 2.38%, or 20 per share, on volume of 28,887 shares.
more»
Faron Pharmaceuticals raises £15mln to establish network for Traumakine launch
20:52 | 16/2/18
Proactive Investors UK
A direct sales model in the US and EU would give an alternative route to market to retain more profits in addition to out-licensing, Faron said. The money will also enable Faron to expand the scope of the upcoming phase I/IIb trial of immunotherapy ...
more»
Faron establishes second Traumakine manufacturing site as it prepares for ...
20:50 | 5/2/18
Proactive Investors UK
The two facilities will support Faron's commercial preparations for Traumakine should the pivotal INTEREST phase III acute respiratory distress syndrome (ARDS) trial return positive results later this year.
more»
Comments
There are currently no comments on this topic.
Be the first person to Add a Comment...
ADD USER TO MY FAVOURITE
Customize your favourite:
Send me an alert when this user publishes new articles.
Add a Comment
You must be a registered user to post a comment:
REGISTER NOW
If you are already registered, please
LOGIN NOW
Add to Watchlist
Add to Portfolio
Add Email Alert
Global Indices
Code
Last
Change
COMP
10,321
328
3.08%
DJI
29,635
404
1.34%
SP500
3,583
87
2.37%
DAX
12,438
82
0.67%
FTSE
7,488
5
0.07%
NI225
22,420
408
1.86%
TWI
67.27
0.00
0.00%
Most Viewed Stories
More news...
No news available...
Currencies
Code
Last
Change
EURUSD
0.9721
0.0055
0.56%
NZDUSD
0.5548
0.0093
1.65%
AUDUSD
0.6194
0.0107
1.70%
NZDAUD
0.8964
0.0010
0.11%
Newsletters
Email Address:
Weekly Newsletter
Daily Market Report
Daily Forex Report
Daily Global Report